Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy.
Sander C EbbersTessa BrabanderMargot E T TesselaarJohannes HoflandManon N G J A BraatFrank J WesselsMaarten W BarentszMarnix G E H LamArthur Johannes Anthonius Theodorus BraatPublished in: EJNMMI research (2022)
Ho]-radioembolization is limited and temporary, while significant additional benefit can be expected. Change in NLR and TLR at 3-weeks follow-up may be valuable early predictors of response. Trial registration ClinicalTrials.gov, NCT02067988. Registered 20 February 2014, https://clinicaltrials.gov/ct2/show/record/NCT02067988 .
Keyphrases
- neuroendocrine tumors
- liver metastases
- squamous cell carcinoma
- toll like receptor
- small cell lung cancer
- computed tomography
- study protocol
- inflammatory response
- phase iii
- immune response
- image quality
- dual energy
- clinical trial
- contrast enhanced
- phase ii
- magnetic resonance imaging
- positron emission tomography
- randomized controlled trial
- gestational age
- pi k akt
- binding protein
- mesenchymal stem cells
- cell therapy
- preterm birth